1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Vermillion, Inc. (VRML) - Product Pipeline Analysis, 2015 Update

Summary

Vermillion, Inc. (Vermillion) is a healthcare service provider that develops and commercializes multi-marker, diagnostic tests which addresses unmet needs in gynecologic oncology and women’s health. The company’s products includes OVA1 product. Its OVA1 is a simple blood test which measures the levels of five proteins found in the blood and then uses a proprietary software called OvaCalc to calculate a single score. Vermillion’s research and development center develops and validates biomarkers and algorithms. The company collaborates with other academic institutions in oncology, cardiology and women’s health. Vermillion is headquartered in Austin, Texas, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Vermillion, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table Of Contents

Vermillion, Inc. (VRML) - Product Pipeline Analysis, 2015 Update
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Vermillion, Inc. Company Snapshot 6
Vermillion, Inc. Company Overview 6
Key Information 6
Vermillion, Inc. Pipeline Products and Clinical Trials Overview 7
Vermillion, Inc. - Pipeline Analysis Overview 9
Key Facts 9
Vermillion, Inc. - Major Products and Services 10
Vermillion, Inc. Pipeline Products by Development Stage 11
Vermillion, Inc. Pipeline Products Overview 13
Biomarker Assay - Breast Cancer 13
Biomarker Assay - Breast Cancer Product Overview 13
Biomarker Test - Prostate Cancer 14
Biomarker Test - Prostate Cancer Product Overview 14
Diagnostic Assay - Alzheimer's Disease 15
Diagnostic Assay - Alzheimer's Disease Product Overview 15
Diagnostic Assay - Colorectal Cancer 16
Diagnostic Assay - Colorectal Cancer Product Overview 16
MammoCheck 17
MammoCheck Product Overview 17
OVA2 18
OVA2 Product Overview 18
OvaCheck 2 19
OvaCheck 2 Product Overview 19
ProstaCheck 20
ProstaCheck Product Overview 20
VASCLIR 21
VASCLIR Product Overview 21
Vermillion, Inc. - Key Competitors 22
Vermillion, Inc. - Key Employees 23
Vermillion, Inc. - Locations And Subsidiaries 24
Head Office 24
Other Locations and Subsidiaries 24
Recent Developments 26
Vermillion, Inc., Recent Developments 26
Sep 01, 2015: Vermillion Announces Launch of New Website in Conjunction with Ovarian Cancer Awareness Month 26
Aug 19, 2015: Vermillion Announces Key Medical Policy Coverage for OVA1 Test 26
Aug 13, 2015: Vermillion Reports Second Quarter 2015 Financial Results and Business Update 26
Jul 13, 2015: ASPiRA Labs Receives New York State Permit 27
May 14, 2015: Positive Top-Line Results Regarding OVA2 Development and Clinical Validation to be Presented at American Society for Clinical Oncology Conference 27
May 11, 2015: Vermillion Reports First Quarter 2015 Financial Results and Provides Business Update 29
Apr 27, 2015: Vermillion Announces Expanded Medical Policy Coverage for OVA1 Test 29
Apr 02, 2015: Vermillion Names Fred Ferrara to Newly Created CIO Post 30
Mar 25, 2015: Vermillion Reports Fourth Quarter and Full Year 2014 Results 30
Mar 17, 2015: Vermillion and Quest Diagnostics Announce New Commercial Agreement 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Vermillion, Inc., Key Facts 6
Vermillion, Inc. Pipeline Products and Clinical Trials Overview 7
Vermillion, Inc. Pipeline Products by Equipment Type 7
Vermillion, Inc. Pipeline Products by Indication 8
Vermillion, Inc., Key Facts 9
Vermillion, Inc., Major Products and Services 10
Vermillion, Inc. Number of Pipeline Products by Development Stage 11
Vermillion, Inc. Pipeline Products Summary by Development Stage 12
Biomarker Assay - Breast Cancer - Product Status 13
Biomarker Assay - Breast Cancer - Product Description 13
Biomarker Test - Prostate Cancer - Product Status 14
Biomarker Test - Prostate Cancer - Product Description 14
Diagnostic Assay - Alzheimer's Disease - Product Status 15
Diagnostic Assay - Alzheimer's Disease - Product Description 15
Diagnostic Assay - Colorectal Cancer - Product Status 16
Diagnostic Assay - Colorectal Cancer - Product Description 16
MammoCheck - Product Status 17
MammoCheck - Product Description 17
OVA2 - Product Status 18
OVA2 - Product Description 18
OvaCheck 2 - Product Status 19
OvaCheck 2 - Product Description 19
ProstaCheck - Product Status 20
ProstaCheck - Product Description 20
VASCLIR - Product Status 21
VASCLIR - Product Description 21
Vermillion, Inc., Key Employees 23
Vermillion, Inc., Subsidiaries 24

List of Figures
Vermillion, Inc. Pipeline Products by Equipment Type 8
Vermillion, Inc. Pipeline Products by Development Stage 11

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase ITK/TSK (Interleukin 2 Inducible T Cell Kinase or T Cell Specific Kinase or Kinase EMT or Tyrosine Protein Kinase Lyk or ITK or EC 2.7.10.2) - Pipeline Review, H2 2016 Summary Global ...

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Histone Deacetylase 1 (HDAC1 or EC 3.5.1.98) - Pipeline Review, H2 2016’, provides in depth ...

Metastatic Ovarian Cancer - Pipeline Review, H2 2016

Metastatic Ovarian Cancer - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • October 2016
  • by Global Markets Direct

Metastatic Ovarian Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Metastatic Ovarian Cancer - Pipeline Review, H2 2016, provides ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.